Who Buys Digoxin from India — 293 Importers Behind a $2.2M Market

The importers of Digoxin from India can be categorized into several key segments:

1. Distributors: Entities such as NORTHSTAR DISTRIBUTION CENTER 8912 and SUN PHARMACEUTICAL INDUSTRIES, INC. in the United States fall into this category. These distributors typically procure large volumes to supply hospitals, pharmacies, and other healthcare providers. Their purchasing patterns are characterized by bulk orders and a focus on maintaining a consistent supply chain to meet market demand.

2. Contract Manufacturers: Companies like SUN PHARMACEUTICAL INDUSTRIES INC. in the United States often engage in contract manufacturing. They import Digoxin as an active pharmaceutical ingredient (API) for formulation and packaging under their brand names. Their procurement is driven by production schedules and market forecasts, leading to periodic, sizable orders.

3. Retail Chains: Entities such as JAMP PHARMA CORPORATION in Canada represent retail chains that import Digoxin to stock their pharmacy outlets. Their buying behavior is influenced by consumer demand, leading to regular, moderate-sized orders to ensure product availability without overstocking.

4. Government Procurement: Organizations like F.D.E.C.A in Ecuador and LEBOO HEALTHCARE PRODUCTS C.A in Venezuela are indicative of government procurement agencies. They often purchase Digoxin through tender-based systems to supply public healthcare facilities. Their orders are typically large and scheduled according to national healthcare needs and budget allocations.

5. Re-exporters: Companies such as ACTIVO INGREDINETS PTE LTD. in Singapore may act as re-exporters, importing Digoxin for distribution to neighboring countries. Their purchasing patterns are opportunistic, based on regional demand fluctuations and trade agreements.

6. Hospital Groups: While not explicitly listed among the top buyers, hospital groups in countries like Nigeria and Sri Lanka may also import Digoxin directly. Their procurement is driven by patient needs and therapeutic requirements, leading to consistent, demand-based ordering.

United States

1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process for Digoxin: Importers must ensure that Digoxin complies with FDA regulations, including proper labeling and registration. Affirmation of Compliance codes such as Drug Registration Number (REG), Drug Listing Number (DLS), and Drug Application Number (DA) are utilized to facilitate FDA review.

3. Estimated Timeline for Registration: The timeline varies based on compliance and documentation but can range from a few weeks to several months.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS Code 30049099 are generally subject to a 0% import duty in the United States.

Sri Lanka

1. Drug Regulatory Authority: National Medicines Regulatory Authority (NMRA).

2. Import Registration Process for Digoxin: Importers must obtain prior approval from the NMRA, including product registration and import licensing.

3. Estimated Timeline for Registration: The registration process typically takes 6 to 12 months, depending on the completeness of the application and regulatory reviews.

4. Import Tariff/Duty for HS 30049099: Pharmaceuticals under this HS code are generally exempt from import duties in Sri Lanka.

Venezuela

1. Drug Regulatory Authority: Instituto Nacional de Higiene Rafael Rangel (INHRR).

2. Import Registration Process for Digoxin: Requires product registration with INHRR, including submission of quality, safety, and efficacy data.

3. Estimated Timeline for Registration: The process can take approximately 12 to 18 months, subject to regulatory assessments and potential delays.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products may be subject to import duties; however, specific rates can vary and should be confirmed with Venezuelan customs authorities.

Canada

1. Drug Regulatory Authority: Health Canada.

2. Import Registration Process for Digoxin: Importers must ensure that Digoxin is authorized for sale in Canada, complying with Health Canada's regulations. In cases of drug shortages, Health Canada maintains a list of drugs eligible for exceptional importation and sale. (canada.ca)

3. Estimated Timeline for Registration: Standard registration can take 6 to 12 months, while exceptional importation processes may be expedited.

4. Import Tariff/Duty for HS 30049099: Pharmaceuticals under this HS code are typically duty-free in Canada.

Nigeria

1. Drug Regulatory Authority: National Agency for Food and Drug Administration and Control (NAFDAC).

2. Import Registration Process for Digoxin: Requires product registration with NAFDAC, including submission of dossiers detailing product information and compliance with Nigerian standards.

3. Estimated Timeline for Registration: The registration process usually takes 6 to 12 months, depending on the thoroughness of the application and regulatory reviews.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products may be subject to import duties; specific rates should be verified with Nigerian customs authorities.

The demand for Digoxin in importing countries is primarily driven by the prevalence of cardiovascular diseases, particularly atrial fibrillation and heart failure, conditions for which Digoxin is a standard treatment. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, accounting for approximately 17.9 million deaths annually as of 2025. This high disease burden necessitates a steady supply of effective medications like Digoxin.

Government healthcare programs and the expansion of universal health coverage also significantly influence Digoxin demand. Many countries have incorporated Digoxin into their national essential medicines lists, aligning with the WHO Model List of Essential Medicines, which emphasizes the importance of such drugs in primary healthcare. Tender-based procurement systems are commonly employed by governments and international organizations to ensure the availability of essential medicines. For instance, the WHO's Disease Control Priorities initiative highlights the critical role of efficient procurement processes in maintaining drug supplies. The presence of 293 buyers across 104 countries, as per our data, underscores the global reliance on Digoxin and the opportunities for suppliers to meet this widespread demand.

The importers of Digoxin from India can be categorized into several key segments:

1. Distributors: Entities such as NORTHSTAR DISTRIBUTION CENTER 8912 and SUN PHARMACEUTICAL INDUSTRIES, INC. in the United States fall into this category. These distributors typically procure large volumes to supply hospitals, pharmacies, and other healthcare providers. Their purchasing patterns are characterized by bulk orders and a focus on maintaining a consistent supply chain to meet market demand.

2. Contract Manufacturers: Companies like SUN PHARMACEUTICAL INDUSTRIES INC. in the United States often engage in contract manufacturing. They import Digoxin as an active pharmaceutical ingredient (API) for formulation and packaging under their brand names. Their procurement is driven by production schedules and market forecasts, leading to periodic, sizable orders.

3. Retail Chains: Entities such as JAMP PHARMA CORPORATION in Canada represent retail chains that import Digoxin to stock their pharmacy outlets. Their buying behavior is influenced by consumer demand, leading to regular, moderate-sized orders to ensure product availability without overstocking.

4. Government Procurement: Organizations like F.D.E.C.A in Ecuador and LEBOO HEALTHCARE PRODUCTS C.A in Venezuela are indicative of government procurement agencies. They often purchase Digoxin through tender-based systems to supply public healthcare facilities. Their orders are typically large and scheduled according to national healthcare needs and budget allocations.

5. Re-exporters: Companies such as ACTIVO INGREDINETS PTE LTD. in Singapore may act as re-exporters, importing Digoxin for distribution to neighboring countries. Their purchasing patterns are opportunistic, based on regional demand fluctuations and trade agreements.

6. Hospital Groups: While not explicitly listed among the top buyers, hospital groups in countries like Nigeria and Sri Lanka may also import Digoxin directly. Their procurement is driven by patient needs and therapeutic requirements, leading to consistent, demand-based ordering.

United States

1. Drug Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process for Digoxin: Importers must ensure that Digoxin complies with FDA regulations, including proper labeling and registration. Affirmation of Compliance codes such as Drug Registration Number (REG), Drug Listing Number (DLS), and Drug Application Number (DA) are utilized to facilitate FDA review.

3. Estimated Timeline for Registration: The timeline varies based on compliance and documentation but can range from a few weeks to several months.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS Code 30049099 are generally subject to a 0% import duty in the United States.

Sri Lanka

1. Drug Regulatory Authority: National Medicines Regulatory Authority (NMRA).

2. Import Registration Process for Digoxin: Importers must obtain prior approval from the NMRA, including product registration and import licensing.

3. Estimated Timeline for Registration: The registration process typically takes 6 to 12 months, depending on the completeness of the application and regulatory reviews.

4. Import Tariff/Duty for HS 30049099: Pharmaceuticals under this HS code are generally exempt from import duties in Sri Lanka.

Venezuela

1. Drug Regulatory Authority: Instituto Nacional de Higiene Rafael Rangel (INHRR).

2. Import Registration Process for Digoxin: Requires product registration with INHRR, including submission of quality, safety, and efficacy data.

3. Estimated Timeline for Registration: The process can take approximately 12 to 18 months, subject to regulatory assessments and potential delays.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products may be subject to import duties; however, specific rates can vary and should be confirmed with Venezuelan customs authorities.

Canada

1. Drug Regulatory Authority: Health Canada.

2. Import Registration Process for Digoxin: Importers must ensure that Digoxin is authorized for sale in Canada, complying with Health Canada's regulations. In cases of drug shortages, Health Canada maintains a list of drugs eligible for exceptional importation and sale. (canada.ca)

3. Estimated Timeline for Registration: Standard registration can take 6 to 12 months, while exceptional importation processes may be expedited.

4. Import Tariff/Duty for HS 30049099: Pharmaceuticals under this HS code are typically duty-free in Canada.

Nigeria

1. Drug Regulatory Authority: National Agency for Food and Drug Administration and Control (NAFDAC).

2. Import Registration Process for Digoxin: Requires product registration with NAFDAC, including submission of dossiers detailing product information and compliance with Nigerian standards.

3. Estimated Timeline for Registration: The registration process usually takes 6 to 12 months, depending on the thoroughness of the application and regulatory reviews.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products may be subject to import duties; specific rates should be verified with Nigerian customs authorities.

The demand for Digoxin in importing countries is primarily driven by the prevalence of cardiovascular diseases, particularly atrial fibrillation and heart failure, conditions for which Digoxin is a standard treatment. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, accounting for approximately 17.9 million deaths annually as of 2025. This high disease burden necessitates a steady supply of effective medications like Digoxin.

Government healthcare programs and the expansion of universal health coverage also significantly influence Digoxin demand. Many countries have incorporated Digoxin into their national essential medicines lists, aligning with the WHO Model List of Essential Medicines, which emphasizes the importance of such drugs in primary healthcare. Tender-based procurement systems are commonly employed by governments and international organizations to ensure the availability of essential medicines. For instance, the WHO's Disease Control Priorities initiative highlights the critical role of efficient procurement processes in maintaining drug supplies. The presence of 293 buyers across 104 countries, as per our data, underscores the global reliance on Digoxin and the opportunities for suppliers to meet this widespread demand.